Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Testosterone replacement ameliorates nonalcoholic fatty liver disease in castrated male rats.

Endocrinology | 2014

Nonalcoholic fatty liver disease is common in developed countries and is associated with obesity, metabolic syndrome, and type 2 diabetes. T deficiency is a risk factor for developing these metabolic deficiencies, but its role in hepatic steatosis has not been well studied. We investigated the effects of T on the pathogenesis of hepatic steatosis in rats fed a high-fat diet (HFD). Adult male rats were randomly placed into four groups and treated for 15 weeks: intact rats on regular chow diet (RCD), intact rats on liquid HFD (I+HFD), castrated rats on HFD (C+HFD), and castrated rats with T replacement on HFD (C+HFD+T). Fat contributed 71% energy to the HFD but only 16% of energy to the RCD. Serum T level was undetectable in castrated rats, and T replacement led to 2-fold higher mean serum T levels than in intact rats. C+HFD rats gained less weight but had higher percentage body fat than C+HFD+T. Severe micro- and macrovesicular fat accumulated in hepatocytes with multiple inflammatory foci in the livers of C+HFD. I+HFD and C+HFD+T hepatocytes demonstrated only mild to moderate microvesicular steatosis. T replacement attenuated HFD-induced hepatocyte apoptosis in castrated rats. Serum glucose and insulin levels were not increased with HFD in any group. Immunoblots showed that insulin-regulated proteins were not changed in any group. This study demonstrates that T deficiency may contribute to the severity of hepatic steatosis and T may play a protective role in hepatic steatosis and nonalcoholic fatty liver disease development without insulin resistance.

Pubmed ID: 24280056 RIS Download

Associated grants

  • Agency: NCATS NIH HHS, United States
    Id: UL1 TR000124
  • Agency: NIDDK NIH HHS, United States
    Id: T32 DK007571
  • Agency: NCATS NIH HHS, United States
    Id: 1UL1TR000124
  • Agency: NCRR NIH HHS, United States
    Id: M01 RR000425
  • Agency: NIAAA NIH HHS, United States
    Id: P50 AA011999
  • Agency: NIDDK NIH HHS, United States
    Id: T32DK007571
  • Agency: NCRR NIH HHS, United States
    Id: MO1 RR00425

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


CPTI-L (H-95) (antibody)

RRID:AB_2084681

This polyclonal targets CPTI-L (H-95)

View all literature mentions

CPTI (N-17) (antibody)

RRID:AB_2084683

This polyclonal targets CPT1A

View all literature mentions

Fatty Acid Synthase (H-300) (antibody)

RRID:AB_2101095

This polyclonal targets FASN

View all literature mentions

HSL/LIPE antibody (antibody)

RRID:AB_2135367

This polyclonal targets LIPE

View all literature mentions

PARP Antibody (antibody)

RRID:AB_2160739

This polyclonal targets PARP

View all literature mentions

Anti-SREBP1 antibody [2A4] (antibody)

RRID:AB_303650

This monoclonal targets SREBP1

View all literature mentions

PPAR alpha antibody (antibody)

RRID:AB_448110

This polyclonal targets PPAR alpha

View all literature mentions